Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ProQR ( (PRQR) ) just unveiled an update.
On June 26, 2025, ProQR Therapeutics announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency for a Phase 1 clinical trial of AX-0810, targeting NTCP, a liver cell protein. This marks a significant milestone as it is the first clinical application of ProQR’s Axiomer RNA editing platform. The trial will evaluate the safety and pharmacokinetics of AX-0810 in healthy volunteers, with initial data expected in Q4 2025. This development is crucial for ProQR’s positioning in the RNA therapy industry, potentially offering a novel therapeutic approach for cholestatic liver diseases.
The most recent analyst rating on (PRQR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
ProQR’s stock score is driven by strong revenue growth and positive market momentum, but is significantly hindered by financial instability, negative cash flows, and unattractive valuation metrics.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics is a biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform. The company aims to address both rare and prevalent diseases with unmet medical needs by leveraging RNA editing to modulate protein expression and reverse mutations.
Average Trading Volume: 498,565
Technical Sentiment Signal: Buy
Current Market Cap: $227.3M
For an in-depth examination of PRQR stock, go to TipRanks’ Overview page.